121 related articles for article (PubMed ID: 32407952)
21. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.
Liang BC; Shi ZY; Wang B; Wu P; Kong LC; Yao JL; Li CW; Shi XL
Orthop Surg; 2017 Feb; 9(1):103-109. PubMed ID: 28276638
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
[TBL] [Abstract][Full Text] [Related]
23. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial.
Brixen K; Chapurlat R; Cheung AM; Keaveny TM; Fuerst T; Engelke K; Recker R; Dardzinski B; Verbruggen N; Ather S; Rosenberg E; de Papp AE
J Clin Endocrinol Metab; 2013 Feb; 98(2):571-80. PubMed ID: 23337728
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of elcatonin in postmenopausal women with osteoporosis: a systematic review with network meta-analysis of randomized clinical trials.
Chen WC; Lin EY; Kang YN
Osteoporos Int; 2019 Sep; 30(9):1723-1732. PubMed ID: 31041475
[TBL] [Abstract][Full Text] [Related]
25. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
Papapoulos S; Lippuner K; Roux C; Lin CJ; Kendler DL; Lewiecki EM; Brandi ML; Czerwiński E; Franek E; Lakatos P; Mautalen C; Minisola S; Reginster JY; Jensen S; Daizadeh NS; Wang A; Gavin M; Libanati C; Wagman RB; Bone HG
Osteoporos Int; 2015 Dec; 26(12):2773-83. PubMed ID: 26202488
[TBL] [Abstract][Full Text] [Related]
26. Adherence with bisphosphonate therapy and change in bone mineral density among women with osteoporosis or osteopenia in clinical practice.
Weycker D; Lamerato L; Schooley S; Macarios D; Siu Woodworth T; Yurgin N; Oster G
Osteoporos Int; 2013 Apr; 24(4):1483-9. PubMed ID: 22903292
[TBL] [Abstract][Full Text] [Related]
27. The vitamin D analogue 2MD increases bone turnover but not BMD in postmenopausal women with osteopenia: results of a 1-year phase 2 double-blind, placebo-controlled, randomized clinical trial.
DeLuca HF; Bedale W; Binkley N; Gallagher JC; Bolognese M; Peacock M; Aloia J; Clagett-Dame M; Plum L
J Bone Miner Res; 2011 Mar; 26(3):538-45. PubMed ID: 20890933
[TBL] [Abstract][Full Text] [Related]
28. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
[TBL] [Abstract][Full Text] [Related]
29. Effect of soy isoflavone extract supplements on bone mineral density in menopausal women: meta-analysis of randomized controlled trials.
Taku K; Melby MK; Takebayashi J; Mizuno S; Ishimi Y; Omori T; Watanabe S
Asia Pac J Clin Nutr; 2010; 19(1):33-42. PubMed ID: 20199985
[TBL] [Abstract][Full Text] [Related]
30. The effect of Cissus quadrangularis L. on delaying bone loss in postmenopausal women with osteopenia: A randomized placebo-controlled trial.
Benjawan S; Nimitphong H; Tragulpiankit P; Musigavong O; Prathanturarug S; Pathomwichaiwat T
Phytomedicine; 2022 Jul; 101():154115. PubMed ID: 35523116
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: A systematic review and meta-analysis.
Peng L; Luo Q; Lu H
Medicine (Baltimore); 2017 Dec; 96(49):e8659. PubMed ID: 29245225
[TBL] [Abstract][Full Text] [Related]
32. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
33. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
Bonnick S; De Villiers T; Odio A; Palacios S; Chapurlat R; DaSilva C; Scott BB; Le Bailly De Tilleghem C; Leung AT; Gurner D
J Clin Endocrinol Metab; 2013 Dec; 98(12):4727-35. PubMed ID: 24064689
[TBL] [Abstract][Full Text] [Related]
34. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.
Reginster JY; Felsenberg D; Pavo I; Stepan J; Payer J; Resch H; Glüer CC; Mühlenbacher D; Quail D; Schmitt H; Nickelsen T
Osteoporos Int; 2003 Sep; 14(9):741-9. PubMed ID: 12827224
[TBL] [Abstract][Full Text] [Related]
35. A systematic review and meta-analysis of the effects of isoflavone formulations against estrogen-deficient bone resorption in peri- and postmenopausal women.
Lambert MNT; Hu LM; Jeppesen PB
Am J Clin Nutr; 2017 Sep; 106(3):801-811. PubMed ID: 28768649
[No Abstract] [Full Text] [Related]
36. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.
Hernandez AV; Pérez-López FR; Piscoya A; Pasupuleti V; Roman YM; Thota P; Herrera A
Maturitas; 2019 Nov; 129():12-22. PubMed ID: 31547908
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and Safety of Zoledronic Acid for Treatment of Postmenopausal Osteoporosis: A Meta-Analysis of Randomized Controlled Trials.
Wang C
Am J Ther; 2017; 24(5):e544-e552. PubMed ID: 26938765
[TBL] [Abstract][Full Text] [Related]
38. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
[TBL] [Abstract][Full Text] [Related]
39. New perspectives in the treatment of postmenopausal osteoporosis: ipriflavone.
Moscarini M; Patacchiola F; Spacca G; Palermo P; Caserta D; Valenti M
Gynecol Endocrinol; 1994 Sep; 8(3):203-7. PubMed ID: 7847106
[TBL] [Abstract][Full Text] [Related]
40. Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients.
Kamimura M; Nakamura Y; Ikegami S; Uchiyama S; Kato H; Taguchi A
Osteoporos Int; 2017 Feb; 28(2):559-566. PubMed ID: 27650642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
